Revolutionizing Early Cancer Screening with Nature and Technology
The Imperative of Early Cancer Identification: Enhancing Survival Prospects
Detecting cancer in its nascent stages is paramount for significantly improving patient outcomes and overall survival rates. Current options for multi-cancer early detection (MCED) tests are undergoing intensive research, with some commercial offerings available, though often at a premium cost and without full regulatory approval. These include blood tests and comprehensive body scans, which can be financially burdensome for individuals.
A Novel Screening Solution Emerges: Bridging Biology and AI
A new frontier in cancer screening is on the horizon, presented by SpotitEarly, a biotech firm participating in the Startup Battlefield at TechCrunch Disrupt 2025. This company is developing an innovative at-home breath test that leverages the exceptional scent detection capabilities of dogs, augmented by artificial intelligence, to identify various cancer types.
Canine Olfaction: Unveiling Cancer's Subtle Scent
Shlomi Madar, CEO of SpotitEarly, emphasizes the growing scientific evidence supporting dogs' ability to detect human diseases, particularly cancer, through scent. He noted anecdotal observations where companion animals have alerted owners to health issues long before medical diagnoses. This insight forms the foundation of SpotitEarly's methodology.
From Concept to Clinical Application: A Collaborative Endeavor
Leveraging his extensive background in health and biotech, Madar collaborated with three colleagues, including a former K9 unit commander, to engineer a robust system for cancer screening using breath samples. The process is straightforward: individuals provide a breath sample at home, which is then sent to SpotitEarly’s laboratory for analysis.
The Hybrid Detection System: Dogs and AI in Concert
At the core of SpotitEarly's system are 18 expertly trained beagles, specialized in identifying specific cancer-related odors. These dogs are trained to signal the presence of cancer particles by sitting. Crucially, their responses are simultaneously verified by an AI platform that monitors their physiological data, such as breathing patterns and heart rates. This integrated approach ensures greater accuracy by eliminating reliance solely on human interpretation.
Verifying Efficacy: Scientific Validation of the Canine-AI Method
The company's research, published in Nature's Scientific Reports, attests to the high accuracy—94%—of their trained dogs in detecting early-stage cancer from breath samples. This double-blind clinical trial involved 1,400 participants and focused on the four most prevalent cancers: breast, colorectal, prostate, and lung cancer.
Strategic Expansion and Future Accessibility: Bringing Innovation to the Forefront
Founded in Israel in 2020, SpotitEarly recently expanded into the U.S. market, supported by $20.3 million in funding from prominent investors including Hanaco VC, Menomedin VC, Jeff Swartz (formerly of Timberland), and Avishai Abrahami (CEO of Wix.com). This capital will fuel further clinical studies, initially concentrating on breast cancer before expanding to other targeted cancers. SpotitEarly aims to make its at-home screening kits available to consumers through a network of physicians next year, with competitive pricing designed to enhance accessibility, offering single cancer tests for approximately $250 and multi-cancer panels at a fraction of the cost of existing alternatives.
A Culture of Care: Prioritizing the Canine Team
Madar underscores the integral role of the dogs within the company, stating that all employees must be "dog people." He emphasizes that the dogs are valued team members, provided with ample space for play and activity, highlighting their dual role as highly skilled biosensors and cherished companions.
